Cambridge-based biopharmaceutical company Aegerion Pharmaceuticals Inc. said the Nasdaq has halted trading of the company's common stock today as a U.S. Food and Drug Administration Advisory panel meets to discuss its new drug application for its lead candidate, lomitapide.
Aegerion said it is seeking FDA marketing approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with homozygous familial hypercholesterolemia, a rare life-threatening disease characterized by severely elevated cholesterol levels.
The FDA has assigned a Prescription Drug User Free Act action date of Dec. 29 for completion of its review of the NDA for lomitapide, Aegerion said.
Anda sedang membaca artikel tentang
Aegerion stock trades halted as FDA reviews drug
Dengan url
http://wartegjokowi.blogspot.com/2012/10/aegerion-stock-trades-halted-as-fda.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Aegerion stock trades halted as FDA reviews drug
namun jangan lupa untuk meletakkan link
Aegerion stock trades halted as FDA reviews drug
sebagai sumbernya
0 komentar:
Posting Komentar